Efficacy and Safety of Ocrelizumab in Patients With RRMS With Suboptimal Response to Prior Disease-Modifying Therapies: 3-Year Data From CASTING and LIBERTO (LIBERTO 1-Year Interim Results)

Authors
Category Primary study
JournalNeurology
Year 2022
This article has no abstract
Epistemonikos ID: 6e13b3e04dc003ec71b281d92fdad820b3e9c7ac
First added on: Feb 14, 2025